Member Info for DP64

S6,
You do not have what type of scam is this VAL. Absolutely scam run by two crroks and were forced out of the company. Recruited 12 patients in 6 years. Both of them should be jailed

Hi gixer,
You are our PXS hero like Thoth2 is SAR board. Many thanks for your wonderful thought. Hope not too long to wait till we get the blue hat approval and then a bidding war between DSM and BY Health. In that case it will be worth for this marathon wait.

Hi gixer,
Many thanks for your very informative post. Hope By Health will be our saviour and want to buy us outright with the right price tag. Then suddenly DSM wakes up and made a counter offer. Probably SL will have the key decision to go which direction we should go.

I am not sure whether IF will produce any new thing or not as he got used to good cut and paste. I think he need to look at VAL where two kicked out by the share holder like us. He is thinking very comfy position to take annual salary and no one bother to raise any comments about his performance. I am very sure there will be a time where people say enough is enough like VAL.

I think that is a signal. I am not sure whether whether it is good or bad.

IF already did a very good job by cutting and pasting. What a wonderful life style he has. Just get well over £100k for doing cutting and pasting and when money is out use the begging bowl to share holders and the share holders are greedy bunch like me keep on paying him.

Hi Mediman,
Please give us some generic clue if there is any problem to put things to post here.

Guys,
I strongly believe it is between DSM and By-Health because By-Health wants a piece of cake before they make a formal offer to buy PXS. So I think it will be not too long before By-Health is going to make an offer. Sit tight for the lift off like SAR.

I think it is a transfer either between two HNWI or between personal and business account of same HNWI.

For your information I lost a huge amount (beyond your imagination) in VAL after consolidating twice. The previous two employee really use the gravy train and recruit 12 patients in six years. What s sha** to both of them. Hope no one will hire them anymore.

Because SAR has the substances not like VAL no substances just spend huge amount of money with two previous employees. Both of them should be prosecuted for misusing share holder's money.

Hi wellsite,
Good post. Hope 0ur sleeping IF is following all these wonderful research to help those people and sell fruitflow. It is a lifetime opportunity and he must capture it not just by taking his salary and have a very comfortable life.

Just received an e-mail about the following Edison report
Edison email header Company research
20 August 2021
Healthcare - Mcap £258m - Price 7.65p - Flash note
Sareum Holdings:
Fund raising to cushion pipeline risk
Sareum released a trading update on 19 August ahead of its full-year results (financial year end 30 June 2021) expected in October 2021. Final pre-clinical studies on the lead asset, TYK2/JAK1 inhibitor SDC-1801, are now expected to commence in Q421 (previously Q321) due to COVID-19 induced supply disruptions. The timeline for the clinical trial application (CTA) and Phase I clinical trials, however, remains unchanged (end Q421 and early 2022 respectively). Short-term liquidity issues have been alleviated following two subscriptions to high net-worth individuals raising £2.37m in June and a further c £2.18m in July and August 2021. Although increased R&D expenses widened the FY21 net loss to £1.6m (versus £0.96m in FY20), the cash balance has improved (£2.7m at the end of June 2021 versus £1.3m at the end of December 2020).

Year

end

Rev
(£m)

PBT
(£m)

EPS
(p)

DPS
(p)

P/E
(x)

Yield
(%)

06/17

0.0

0.4

0.02

0.0

0.0

N/A

06/18

0.0

(1.5)

(0.06)

0.0

0.0

N/A

06/19

0.0

(1.5)

(0.05)

0.0

0.0

N/A

06/20

0.04

(1.0)

(0.03)

0.0

0.0

N/A

Research note thumbnail
Read more >
Business description
Sareum is a UK-based drug development company, specialising in small molecule kinase inhibitors. Its flagship programmes are its pre-clinical TYK2/JAK1 inhibitors, SDC-1801 for autoimmune diseases and SDC-1802 for cancer. SDC-1801 is undergoing advanced dose finding and toxicology studies with a target to file a CTA in end-2021. Other programmes include the CHK1 inhibitor SRA737, out licensed to Sierra Oncology (Sareum holds a 27.5% stake of the economics of the licence agreement) and the deprioritised FLT3+Aurora kinase.

Sareum Holdings is a research client of Edison Investment Research

Analyst

Jyoti Prakash, healthcare analyst
healthcare@edisongroup.com
+44 020 3077 5700

No. I think that is bed&ISA. So someone is transferring from normal investment account to ISA.

Hi CornishTrig,
Just matter of interest is it based on some mathematical model or just your assumption.

Hi Thoth2,
I will recommend you this natural ingredients from
https://www.fruitflowplus.com/

Mefakescientist,
Great post mate. It will start flying from Monday.

Hi gixer,
That is not a good publicity for DSM and provexis as fruitflow was mentioned in the report.

Brighty1,
Great post mate with very good summary. Yes it will blow our imagination totally off the track when all the deals will land.

Hi RMM,
Great post mate. Very well presented summary and fully agreed. SAR is a once in a lifetime opportunity. It is going to blow our wildest dream.